0001683168-21-006502.txt : 20211222 0001683168-21-006502.hdr.sgml : 20211222 20211222080147 ACCESSION NUMBER: 0001683168-21-006502 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211220 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211222 DATE AS OF CHANGE: 20211222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52898 FILM NUMBER: 211511023 BUSINESS ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 BUSINESS PHONE: 514-426-6161 MAIL ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 8-K 1 sunshine_8k.htm CURRENT REPORT

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

December 20, 2021

SUNSHINE BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Colorado

000-52898

20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R0A5

(Address of principal executive offices)

(514) 426-6161

(Issuer’s Telephone Number)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
N/A	N/A	N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.02

Unregistered Sale of Equity Securities

Effective December 20, 2021, we issued 2,904,833 shares of our Common Stock in favor of RB Capital Partners, Inc. (“RB Capital”) in connection with the conversion of $1,361,000 in convertible debt at an average conversion price of $0.47 per share.

We relied upon the exemption from registration provided by Section 4/2 as promulgated under the Securities Act of 1933, as amended, to issue these shares.

Item 7.01

Regulation FD Disclosure

Attached is a copy of a press release being issued by us relating to the issuance of the shares and corresponding reduction of debt more fully described in Item 3.02 above herein, which is attached as Exhibit 99.1 and is hereby incorporated.

Item 9.01

Financial Statements and Exhibits

(b) Exhibits. The following exhibits are included in this report:

No.		Description
99.1		Press Release announcing the issuance of the shares and corresponding reduction of debt.
104		Cover Page Interactive Data File (formatted in iXBRL)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 22, 2021	SUNSHINE BIOPHARMA, INC.
	(Registrant)

	By: s/ Dr. Steve N. Slilaty
	Dr. Steve N. Slilaty, Chief Executive Officer

3

EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE

Exhibit 99.1

For Immediate Release

December 22, 2021

Sunshine Biopharma Announces $1,361,000 in Debt Reduction

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that on December 20, 2021, the Company issued 2,904,833 shares of Common Stock in favor of RB Capital Partners, Inc. (“RB Capital”) in connection with the conversion of $1,361,000 in convertible debt at an average conversion price of $0.47 per share. The total debt remaining on the books of the Company is $1,900,000 convertible at an average price of $0.30 per share with maturity dates in April, July and August 2023.

“This debt conversion strengthens the financial condition of the Company and conserves the cash on hand for our ongoing research and development activities of our antiviral and anticancer drugs,” said, Camille Sebaaly, CFO of Sunshine Biopharma. “We thank RB Capital for believing in us and for their continued support,” he added.

About Sunshine Biopharma

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

1

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

2

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 sbfm-20211220.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sbfm-20211220_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 sbfm-20211220_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 20, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 20, 2021
Entity File Number	000-52898
Entity Registrant Name	SUNSHINE BIOPHARMA, INC.
Entity Central Index Key	0001402328
Entity Tax Identification Number	20-5566275
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	6500 Trans-Canada Highway
Entity Address, Address Line Two	4th Floor
Entity Address, City or Town	Pointe-Claire
Entity Address, State or Province	QC
Entity Address, Country	CA
Entity Address, Postal Zip Code	H9R0A5
City Area Code	(514)
Local Phone Number	426-6161
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 8 sunshine_8k_htm.xml IDEA: XBRL DOCUMENT 0001402328 2021-12-20 2021-12-20 iso4217:USD shares iso4217:USD shares 0001402328 false 8-K 2021-12-20 SUNSHINE BIOPHARMA, INC. CO 000-52898 20-5566275 6500 Trans-Canada Highway 4th Floor Pointe-Claire QC CA H9R0A5 (514) 426-6161 false false false false true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sunshine_8k.htm sbfm-20211220.xsd sbfm-20211220_lab.xml sbfm-20211220_pre.xml sunshine_ex9901.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sunshine_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sunshine_8k.htm" ] }, "labelLink": { "local": [ "sbfm-20211220_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20211220_pre.xml" ] }, "schema": { "local": [ "sbfm-20211220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20211220", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "sunshine_8k.htm", "contextRef": "From2021-12-20to2021-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://sunshinebiopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "sunshine_8k.htm", "contextRef": "From2021-12-20to2021-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001683168-21-006502-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-006502-xbrl.zip M4$L#!!0 ( #= EE-KM:R=.0, @, 1 \K M^08!0X"T?I)7YYS=E7;7;ETOHA#,$..8DK9F&Y8&$/&HC\FXK3TX^F?GIMO5 MP/75N[= /JWWN@XZ&(5^$]Q23^^2@%Z"'S!"37"'"&)04'8)'F&8* OMX! Q M<$.C.$0"R8W,4Q,T#-MR@:X?H/N(B$_9P[!;ZDZ$B'G3-.?SN4'H#,XIFW+# MH]%A@HZ (N&EFK6P\N

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